| Literature DB >> 32837850 |
Sadaf Farasat1, Jennifer J Dorsch2,3, Alex K Pearce4, Alison A Moore5, Jennifer L Martin6,7, Atul Malhotra4, Biren B Kamdar4.
Abstract
Purpose of Review: Poor sleep and delirium are common in older patients but recognition and management are challenging, particularly in the intensive care unit (ICU) setting. The purpose of this review is to highlight current research on these conditions, their inter-relationship, modes of measurement, and current approaches to management. Recent Findings: Sleep deprivation and delirium are closely linked, with shared clinical characteristics, risk factors, and neurochemical abnormalities. Acetylcholine and dopamine are important neurochemicals in the regulation of sleep and wakefulness and their dysregulation has been implicated in development of delirium. In the hospital setting, poor sleep and delirium are associated with adverse outcomes; non-pharmacological interventions are recommended, but tend to be resource intensive and hindered by a lack of reliable sleep measurement tools. Delirium is easier to identify, with validated tools available in both ICU and non-ICU settings; however, an optimal treatment approach remains unclear. Antipsychotics are used widely to prevent and treat delirium, although the efficacy data are equivocal. Bundled non-pharmacologic approaches represent a promising framework for prevention and management. Summary: Poor sleep and delirium are common problems in older patients. While these phenomena appear linked, a causal relationship is not clearly established. At present, there are no established sleep-focused guidelines for preventing or treating delirium. Novel interventions are needed that address poor sleep and delirium, particularly in older adults. © Springer Nature Switzerland AG 2020.Entities:
Keywords: Acetylcholine; Aging; Delirium; Dopamine; Intensive care; Sleep
Year: 2020 PMID: 32837850 PMCID: PMC7382993 DOI: 10.1007/s40675-020-00174-y
Source DB: PubMed Journal: Curr Sleep Med Rep ISSN: 2198-6401
Sleep assessment methods
| Sleep assessment tool | Validated against PSG | Description | Ratings done by | Advantages | Disadvantages |
|---|---|---|---|---|---|
| May also have utility in evaluating sleep during delirium | |||||
| Polysomnography (PSG) [ | Multimodal tool involving electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), respiratory effort, oxygen saturation, and electrocardiography | Data analyzed by computers in real time, confirmed by experts | Gold standard to sleep/wake and sleep stage evaluation in non-critically ill patients Objective Can aid in diagnosis of sleep disorders | Cumbersome, costly, resource intensive, and prone to dislodgement in hospitalized or critically ill patients Vulnerable to misinterpretation in hospitalized patients | |
| EEG [ | Yes | Utilizes numerous scalp leads to measure brain activity; does not include EMG, EOG | Data analyzed by computers in real time, confirmed by experts | High sensitivity and specificity for sleep-wake determination Objective | Interpretation in critically ill patients challenging due to factors (i.e., sedatives) which can affect the EEG pattern Lacks specificity in sleep stage differentiation |
| Odds ratio product (ORP) [ | Yes | EEG-derived continuous estimate of sleep depth, ranging from 0 (deep sleep) to 2.5 (fully awake) | Validated in ambulatory patients | Same interpretation challenges of EEG interpretation | |
| Actigraphy [ | Yes | Accelerometer-based device (often a wristwatch) which measures patient activity | Activity data analyzed by computer algorithm, used to determine sleep-wake | Surrogate for sleep-wake measurement in community settings Noninvasive | Overestimation of “sleep” in mostly inactive hospitalized and/or critically ill patients |
| Do not have utility in evaluating sleep during delirium | |||||
| Richards-Campbell Sleep Questionnaire (RCSQ) [ | Yes | Subjective assessment involving 100 mm visual analogue scale to assess 5 domains of sleep: depth, latency, efficiency, quality, and number of awakenings | Proxies can complete if patients are unable | Brief Easy to administer Inexpensive Can be administered repeatedly | Infeasible in cognitively impaired (e.g., delirious) patients Nurse proxies may overestimate patients’ sleep quality |
| Leeds Sleep Evaluation Questionnaire (LSEQ) [ | No | Subjective assessment involving 10,100 mm visual analogue scales related to falling asleep, sleep quality, awakenings, daytime alertness, feelings, and balance | Completed by patients | Brief Easy to administer Inexpensive | Infeasible in cognitively impaired (e.g., delirious) patients Not validated against PSG |
| Verran/Snyder-Halpern Sleep Scale [ | No | Subjective assessment of sleep over the previous three nights, two visual analogue scales evaluating sleep: disturbance and effectiveness | Completed by patients | Takes longer time to complete than RCSQ | Infeasible in cognitively impaired (e.g., delirious) patients Validated for ages 20–78 years with no history of sleep difficulties |
| Sleep in Intensive Care Unit Questionnaire (SICUQ) [ | No | Subjective 27-item evaluation of sleep quality at home and the ICU environment, on Likert scales of 1–10, with questions about disruptiveness of ICU activities and noises | Completed by patients | Compares subjective assessment of sleep in ICU and at home | Infeasible in cognitively impaired (e.g., delirious) patients Does not account for severity of illness or medication use |
| Saint Mary’s Hospital Sleep Questionnaires (SMHSQ) [ | No | Subjective 14-item evaluation of sleep in the hospital | Completed by patients | Designed for repeated use | Takes longer to complete Low internal consistency |
PSG polysomnography, EEG electroencephalography, EOG electrooculography, EMG electromyography, ORP odds ratio product, RCSQ Richards-Campbell Sleep Questionnaire, LSEQ Leeds Sleep Evaluation Questionnaire, VSH Verran/Snyder-Halpern Sleep Scale, SICUQ Sleep in Intensive Care Unit Questionnaire, SMHSQ Saint Mary’s Hospital Sleep Questionnaires
Delirium assessment methods
| Delirium screening tool | Criteria on which Scale was based | Number of items | Time to complete (minutes) | Ratings done by |
|---|---|---|---|---|
| CAM-ICU [ | DSM-IV | 9 | ≤ 2 | Trained health professional |
| ICDSC [ | DSM-IV | 8 | 7–10 | Non-specialist staff |
| DRS-R-98 (106) | DSM-IV | 16 | 10 | Psychiatrists |
| NEECHAM Confusion Scale [ | Research | 9 | 10 | Nurses |
| Delirium Observation Screening Scale [ | DSM-IV | 25 | 5–10 | Research Assistant |
| Nursing Delirium Screening Scale [ | Research | 5 | 1 | Nurses |
CAM-ICU Confusion Assessment Method for the ICU, DSM Diagnostic and Statistical Manual for Mental Disorders, ICDSC Intensive Care Delirium Screening Checklist, DRS-R-98 Delirium Rating Scale-Revised 98, NEECHAM Neelon-Champagne
Medications commonly used to promote sleep in hospitalized patients [58, 64, 124–126]
| Medication | Mechanism of action | Route of administration | Side effects | Sleep effects | Risk of delirium in older adults |
|---|---|---|---|---|---|
| Listed under Beers criteria | |||||
| Opiates [ | CNS opioid receptor agonist | Oral or intravenous | Dependency, hypotension, respiratory depression, withdrawal | ↓N3, ↓REM, ↓TST, ↑W | ↑ |
| Atypical antipsychotics [ | 5HT2 D2-receptor antagonist | Oral | Dizziness, extrapyramidal symptoms, neuroleptic malignant syndrome, orthostatic hypotension | ↑N3, +/−↑REM, ↑SE, ↓SL, ↑TST, ↓W | No change |
| Typical antipsychotics [ | Dopamine receptor antagonist | Oral or intravenous | Anticholinergic effects, extrapyramidal symptoms, neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia | ↑N2, ↑N3, ↑SE, ↓SL, ↑TST, ↓W | No change |
| Trazodone [ | Serotonin reuptake inhibitor, 5-HT1A,1C,2; H1 receptor antagonist | Oral | Anticholinergic syndrome, arrhythmias, orthostatic hypotension | ↑N3, ↑↓REM, +/−↑SE, ↓SL | +/−↑ |
| Antihistamines [ | H1-receptor antagonist | Oral or intravenous | Anticholinergic syndrome, dizziness, impaired coordination | +/−↑N3, ↓REM, +/−↑SE, ↓SL | ↑ |
| Benzodiazepines [ | GABA receptor agonist | Oral or intravenous | Dependency, deliriogenic, dizziness, hypotension, withdrawal | ↓N3, ↓REM, ↓SL, ↑TST, ↓W | ↑ |
| Non-benzodiazepine hypnotics [ | GABA receptor agonist | Oral | Daytime somnolence, dizziness, confusion | ↓N2, ↓N3, ↑↓REM, ↓SL ↑TST, ↓W | ↑ |
| Not listed under Beers criteria | |||||
| Dexmedetomidine [ | a2-Agonist | Intravenous | Bradycardia, hypotension | ↑N2 with sleep spindles, +/−↑N3/SWS, ↓REM, ↑SE, ↓SL | ↓ |
| Propofol [ | GABA receptor agonist | Intravenous | Bradycardia, hypotension, propofol infusion syndrome, respiratory depression | ↓REM, ↓SL, ↑TST, ↓W | ↑ |
| Melatonin and melatonin receptor agonists [ | Melatonin 1 and 2 receptor agonist | Oral | Dizziness, hallucinations, nausea, vivid dreams | ↑SE, ↓SL, ↑ TST | ↓ |
SWS slow wave sleep, REM rapid eye movement, SE sleep efficiency, SL sleep latency, TST total sleep time, W wake
↓ = decreased; ↑ = increased; ↑↓ = equivocal; +/−↑ = may increase; +/−↓ = may decrease